Athersys (ATHX +16.1%) is up on more than a 4x surge in volume in apparent response to the news that partner HEALIOS K.K. has enrolled the first patient in a study in Japan, ONE-BRIDGE, evaluating MultiStem cell therapy in patients with acute respiratory distress syndrome (ARDS).
The 30-subject trial will compare MuliStem to standard-of-care therapy. The primary endpoint is the number of ventilator-free days in the 28-day period post treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.